Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NicOx Presents Top-Line Results Of NCX 6560 Study
NicOx has reported that a phase 1b, first-in-man study for NCX 6560, versus placebo and Lipitor (atorvastatin), has met its primary and secondary objectives. The primary top-line results
NicOx has reported that a phase 1b, first-in-man study for NCX 6560, versus placebo and Lipitor (atorvastatin), has met its primary and secondary objectives. The primary top-line results
Ipsen has reported that the French Regulatory Authorities (AFSSAPS) have granted the marketing authorisation to the 6-month sustained-release formulation of Decapeptyl (triptorelin embonate1 22.5 mg) for the treatment
BioInvent International has entered into a licence and discovery agreement with Daiichi Sankyo for the development of therapeutic antibodies against multiple targets. Under the terms of the collaboration,
TET Systems has reported that TET Systems and Novo Nordisk have signed a license agreement allowing the Hagedorn Research Institute (HRI), a research institute within Novo Nordisk, the
Axelar has reported that promising data from the ongoing Phase I/II clinical trial concerning their lead anticancer product AXL1717, is expected to be presented at the AACR-NCI-EORTC International
Merck & Co. has released new results from a survey of 1,122 post-menopausal women in Asia found that nearly half (48.5%) were not aware whether or not they
Cadence Pharmaceuticals has announced that the FDA has extended the Prescription Drug User Fee Act (PDUFA) goal date for its priority review of the New Drug Application (NDA)
Emergent BioSolutions has completed the acquisition of a 55,000 square foot manufacturing facility from MdBio foundation and the land on which the facility stands from the city of
Talecris Biotherapeutics and NC Gov Bev Perdue have reported that the company will expand its manufacturing facilities in Clayton, creating 259 new jobs over the next seven years.
Xanodyne pharmaceuticals has received the FDA approval for its Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilising